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Abstract
In this study, we first demonstrate that endogenous hBST-2 is predominantly expressed on the
plasma membrane of a human T cell line, MT-4 cells, and that Vpu-deficient HIV-1 was less
efficiently released than wild-type HIV-1 from MT-4 cells. In addition, surface hBST-2 was rapidly
down-regulated in wild-type but not Vpu-deficient HIV-1-infected cells. This is a direct insight
showing that provirus-encoded Vpu has the potential to down-regulate endogenous hBST-2 from
the surface of HIV-1-infected T cells. Corresponding to previous reports, the aforementioned
findings suggested that hBST-2 has the potential to suppress the release of Vpu-deficient HIV-1.
However, the molecular mechanism(s) for tethering HIV-1 particles by hBST-2 remains unclear,
and we speculated about the requirement for cellular co-factor(s) to trigger or assist its tethering
ability. To explore this possibility, we utilize several cell lines derived from various species including
human, AGM, dog, cat, rabbit, pig, mink, potoroo, and quail. We found that ectopic hBST-2 was
efficiently expressed on the surface of all analyzed cells, and its expression suppressed the release
of viral particles in a dose-dependent manner. These findings suggest that hBST-2 can tether HIV-
1 particles without the need of additional co-factor(s) that may be expressed exclusively in
primates, and thus, hBST-2 can also exert its function in many cells derived from a broad range of
species. Interestingly, the suppressive effect of hBST-2 on HIV-1 release in Vero cells was much less
pronounced than in the other examined cells despite the augmented surface expression of ectopic
hBST-2 on Vero cells. Taken together, our findings suggest the existence of certain cell types in
which hBST-2 cannot efficiently exert its inhibitory effect on virus release. The cell type-specific
effect of hBST-2 may be critical to elucidate the mechanism of BST-2-dependent suppression of
virus release.
Findings
To accomplish efficient release of HIV-1 particles, HIV-1
Vpu is required in certain cells (e.g., HeLa cells) but is dis-
pensable in other cell types (e.g., HEK293 and Cos-7 cells)
[1-3]. A previous report suggested that an inhibitory fac-
tor(s) for HIV-1 release is expressed in HeLa cells and the
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effect is attenuated by Vpu [4]. Recently, Neil and col-
leagues identified the inhibitor, hBST-2 (also called
CD317 or HM1.24), in HeLa cells, and referred to this
protein as "Tetherin" [5]. They also showed that the inhib-
itory action of hBST-2 on HIV-1 particle release was antag-
onized by Vpu, and they concluded that hBST-2 functions
by tethering HIV-1 particles to the cell surface [5]. In addi-
tion, Van Damme and colleagues demonstrated that Vpu
down-regulates hBST-2 from the surface of HeLa cells [6].
On the other hand, Miyagi and colleagues have recently
reported that Vpu augments HIV-1 release without down-
regulating surface hBST-2 in CEMx174 and H9 cells [7].
Therefore, the relevance of surface hBST-2 down-regula-
tion and the antagonistic action of Vpu on the tethering
ability of hBST-2 remain unclear.
We first set out to analyze the level of endogenous hBST-
2 expression in a T cell line (MT-4 cells) and compared
this level to that found for adherent cell lines (HeLa and
HEK293 cells). Although flow cytometry indicated that
the level of surface hBST-2 on MT-4 cells was comparable
to that expressed on HeLa cells, Western blotting indi-
cated that the total amount of endogenous hBST-2 protein
in HeLa cells was much more than the level found in MT-
4 cells (Figures 1A–C). These results indicate that endog-
enous hBST-2 in MT-4 cells is predominantly expressed
on the plasma membrane.
To analyze the sensitivity of endogenous hBST-2 on the
surface of MT-4 cells to Vpu antagonism, MT-4 cells were
infected with either wild-type or Vpu-deficient HIV-1, and
the level of surface hBST-2 was subsequently monitored.
The amount of released virions in the culture supernatant
of wild-type HIV-1-infected cells was significantly higher
when compared to that of Vpu-deleted HIV-1-infected
cells (Figure 1E), while the percentage of p24-positive
cells in wild-type HIV-1-infected culture was similar to
that in Vpu-deleted HIV-1-infected culture (Figure 1F).
These results suggest that the liberation of Vpu-deficient
HIV-1 virions was impaired by endogenous hBST-2 in MT-
4 cells. In addition, we clearly found that the surface
expression of hBST-2 on wild-type but not Vpu-deleted
HIV-1-infected cells (i.e., p24-positive cells) was severely
down-regulated (Figures 1D and 1H). Although it has
remained ambiguous in the literature whether endog-
enous hBST-2 on the surface of human T cells is down-reg-
ulated by HIV-1 infection [6,7], this is the first
demonstration of the significant down-regulation of
endogenous hBST-2 in T cells by Vpu which resulted from
HIV-1 infection and not from transfection with a Vpu-
expressing plasmid [6,8].
Following the rapid down-regulation of surface hBST-2 by
infection with wild-type HIV-1, the surface expression of
hBST-2 was gradually but significantly replenished along
with HIV-1 expansion (Figures 1D and 1H). It is unclear
how and why the surface levels of hBST-2 increased; how-
ever, our finding indicates that the level of down-regula-
tion of surface hBST-2 on HIV-1-infected T cells would
vary depending on the time after infection.
Consistent with previous reports, our findings suggested
that hBST-2 has the potential to attenuate HIV-1 release
[5,6]. However, how hBST-2 acts against the release of
HIV-1 particles remains unclear, and it is not known
whether the hBST-2 function involves additional cellular
co-factor(s). Since the potential of hBST-2 for the suppres-
sion of HIV-1 release has been reported only in primate
cell lines [5-7], we hypothesized that hBST-2 may utilize
co-factor(s) expressed uniquely in primate cells to tether
virions. To investigate the role of hBST-2, we set forward
to use various cell lines derived from 9 animal species
including human, AGM, dog, cat, rabbit, pig, mink,
potoroo, and quail. These cells were transfected with
either wild-type or Vpu-deficient HIV-1-producing plas-
mid (pNL4-3 or pNL43-Udel). The amounts of released
virions from HEK293, Vero, Cos-7, D-17, PK-15, RSC,
Mv.1.Lu, and QT6 cells were quantified by TZM-bl titra-
tion assay [9], while those from CRFK and PtK2 cells were
quantified by p24 ELISA because of their lower infectivity
[10] (Figure 2). As previously described [4-6,11], HeLa
cells were incompetent for the release of Vpu-deficient
HIV-1 (Figure 2). In contrast, the other cell lines examined
here were able to produce almost comparable amounts of
Vpu-deficient HIV-1 when compared to the release of
wild-type HIV-1 (Figure 2). These results indicate the
absence in these examined cells of intrinsic factors which
have the potential to be similar to hBST-2 and can be
antagonized by Vpu.
Previous studies have shown that rhTRIM5α, a well-
known restriction factor for HIV-1 replication [12,13], is
able to efficiently elicit its suppressive ability for HIV-1
replication in feline CRFK cells, but not in canine D-17
cells [14,15]. These results suggest the species-specific
ability of rhTRIM5α to suppress HIV-1 replication. To
investigate the species-specific tethering ability of hBST-2,
we next co-transfected an hBST-2-expressing plasmid
(phBST-2) with either pNL4-3 or pNL43-Udel in the
above examined cell lines and harvested released virions
at 24 hours post-transfection. As shown in Figure 2, exog-
enous hBST-2 in these cell lines clearly suppressed the
release of Vpu-deficient HIV-1 in a dose-dependent man-
ner. This result strongly indicates that hBST-2 can tether
released HIV-1 particles without any other unidentified
co-factors that are expressed exclusively in primates. It
remains conceivable that hBST-2 could employ certain
elements ubiquitously expressed in many species for the
tethering of released virions. Although it has been contro-
versial whether wild-type HIV-1 release can be suppressedRetrovirology 2009, 6:53 http://www.retrovirology.com/content/6/1/53
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Sequential analysis on the level of endogenous hBST-2 on the surface of HIV-1-infected human T cells Figure 1
Sequential analysis on the level of endogenous hBST-2 on the surface of HIV-1-infected human T cells. (A and B) 
MT-4 cells were stained with a mouse anti-hBST-2 antibody, and the surface expression of endogenous hBST-2 (filled in gray) 
was analyzed by flow cytometry as described in the Materials and Methods. Isotype IgG was used as a negative control (broken 
line). A representative result (A) and summarized graph (B) are shown. The level of endogenous hBST-2 on the surface of MT-
4 cells (opened bar and circle) is compared to that of HeLa and HEK293 cells (filled bars and circles). MFI is represented in bars 
(Y-axis on left), and the percentage of hBST-2-positive cells is represented in circles (Y-axis on right, log scale). (C) The level of 
endogenous hBST-2 expression in HeLa, HEK293, and MT-4 cells was analyzed by Western blotting (top panel). For clear 
detection of hBST-2, the cell lysates were treated with glycopeptidase as described in the Materials and Methods, and the level 
of deglycosylated hBST-2 was analysed by Western blotting (bottom panel). The input was standardized to Tubulin, and repre-
sentative results are shown. kDa, kilodalton. (D-H) MT-4 cells were infected with either wild-type or Vpu-deficient HIV-1 
(MOI 0.1). Endogenous hBST-2 on the cell surface and intracellular expression of p24 were sequentially analyzed by flow 
cytometry, and representative profiles are shown (D). The number in the corner of the plot indicates MFI of hBST-2 on the 
surface of whole cells, and that in the square in the plot indicates MFI of hBST-2 on the surface of p24-postive cells. The 
amount of p24 in the culture supernatant (E), the percentage of p24-positive cells (F), the level of hBST-2 on the surface of 
whole cells (G), and the level of hBST-2 on the surface of p24-positive cells (H) following infection with either wild-type 
(opened circles with line) or Vpu-deficient (filled circles in gray with broken line) HIV-1 were sequentially measured. The 
amount of p24 in the culture supernatant was quantified by p24 ELISA, and the other data were obtained by flow cytometry as 
described in the Materials and Methods. Gray line in panel G indicates MFI of surface hBST-2 on mock-infected cells. All exper-
iments were performed in triplicate. Asterisks indicate statistical significance (Student's t test, P < 0.05) versus the values of 
Vpu-deficient HIV-1 at the same time point, and double daggers in panel H indicate statistical significance (Student's t test, P < 
0.05) versus the values of wild-type HIV-1 at 24 hours post-infection. Error bars indicate standard deviations.Retrovirology 2009, 6:53 http://www.retrovirology.com/content/6/1/53
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by ectopic hBST-2 or not [5,6], we observed here that the
release of wild-type HIV-1 was attenuated by hBST-2 and
that the efficiency of hBST-2 for the release of wild-type
HIV-1 was significantly lower than that for the release of
Vpu-deleted HIV-1 (Figure 2).
Ectopically expressed hBST-2 was detected on the surface
of all cell lines used in this study (Figure 3A). Unexpect-
edly, we found the staining with this antibody in native
AGM cell lines, Vero and Cos-7 cells (Figure 3A) that
increased in intensity when treated with IFN-α (data not
shown). It is known that hBST-2 expression is induced
upon IFN-α treatment in HEK293 cells [5,6]. Therefore,
the antibody-specific staining and its increased signal
intensity that we observed in the AGM cells could be due
to the cross-reactivity of the anti-BST-2 antibody with
endogenous AGM BST-2.
As previously reported [6], we also found that endog-
enous hBST-2 on HeLa cells was significantly down-regu-
lated by transfection with pNL4-3, but not with pNL43-
Udel (Figure 3B). In contrast, at 24 hours post-transfec-
tion, the down-regulation of exogenous hBST-2 on the
surface of the other cell lines was hardly observed except
for Vero cells (Figure 3B). However, after 48 hours post-
transfection, we could detect significant down-regulation
of ectopically expressed hBST-2 on the surface of cells co-
transfected with either pNL4-3 or a Vpu-expressing plas-
mid [8] (data not shown). These results suggest that the
level of Vpu expression at 24 hours post-transfection is
sufficient to antagonize the tethering ability of hBST-2,
while not down-regulating surface hBST-2. In support of
our data, a recent report showed that Vpu enhances HIV-
1 release in the absence of surface down-regulation of
hBST-2 [7]. Taken together, these results indicate that the
down-regulation of surface hBST-2 may be dispensable
for the antagonism of tethering ability of hBST-2 by Vpu.
We further assessed the results obtained from all the
examined cell lines and focused on the correlation
between the efficiency of particle release and the level of
surface hBST-2 in these cells. All of the examined cell lines
except for Vero cells showed significant suppression of
virus release by exogenously expressed hBST-2 (Figure 4).
In addition, a direct correlation between the suppression
efficiency for virus release by hBST-2 and the level of sur-
face hBST-2 was found in these cells with high correlation
coefficients (Figure 4) and statistical significance (P  <
Suppression of HIV-1 release by exogenous hBST-2 in various cell lines Figure 2
Suppression of HIV-1 release by exogenous hBST-2 in various cell lines. One microgram of pNL4-3 and pNL43-Udel 
was each co-transfected with (20 or 100 ng) or without (-) phBST-2 into several lines of cells as described in the Materials and 
Methods. The amount of wild-type (opened bars) or Vpu-deficient HIV-1 virion (bars filled in gray) released from HeLa, 
HEK293, Vero, Cos-7, D-17, PK-15, RSC, Mv.1.Lu, and QT6 was quantified by using TZM-bl cells, and the amount of HIV-1 
released from CRFK and PtK2 cells was quantified by p24 ELISA. All experiments were performed in triplicate. Statistical signif-
icance (Student's t test) versus wild-type HIV-1 values is represented as follows: *, P < 0.05; **, P < 0.01. Error bars indicate 
standard deviations. n.d., not detectable.Retrovirology 2009, 6:53 http://www.retrovirology.com/content/6/1/53
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0.01). On the other hand, the suppression efficiency for
virus release by hBST-2 in Vero cells was relatively milder
than in the other 9 cell lines even though Vero cells exhib-
ited the highest levels of hBST-2 cell surface expression
(Figure 4). Moreover, the result from Vero cells displayed
a statistically different pattern than in the other cells (Fig-
ure 4, P < 0.01 by repeated measure ANOVA). These find-
ings suggest that ectopic hBST-2 is unable to efficiently
exert its inhibitory effect on virus release in Vero cells. One
plausible explanation for this anomaly may be attributed
to a defective IFN-α response. Although a previous study
showed that the release of Vpu-deficient HIV-1 was sup-
pressed upon IFN-α treatment [11], Vero cells are known
to be genetically deficient in type I IFN genes, including
IFN-α [16,17]. Therefore, it is conceivable that a signal
cascade mediated by IFN-α may be needed to assist the
tethering action of ectopic hBST-2, but that this cascade
may not be operative in Vero cells because of its defects in
type I IFN genes. Further studies in Vero cells will be
needed to shed light on the unexplained aspects of the
mechanism of suppression of virus release mediated by
hBST-2.
It has recently been reported that hBST-2 has the potential
to suppress the release of not only HIV-1 but also other
retroviruses [18], Ebola virus [18], Lassa virus [19], and
Surface expression of exogenous hBST-2 in various cell lines Figure 3
Surface expression of exogenous hBST-2 in various cell lines. (A) HEK293, Vero, Cos-7, D-17, CRFK, PK-15, RSC, 
Mv.1.Lu, PtK2, and QT6 cells were transiently transfected with 100 ng of phBST-2. phBST-2-transfected cells (black line) and 
mock-transfected cells (filled in gray) as well as HeLa cells (filled in gray) were stained with a mouse anti-hBST-2 monoclonal 
antibody, and the surface expression of hBST-2 was analyzed by flow cytometry as described in the Materials and Methods. Iso-
type IgG was used as a negative control (broken line). A representative result is shown. (B) One microgram of pNL4-3 and 
pNL43-Udel was each co-transfected with (20 or 100 ng) or without (-) phBST-2 into several lines of cells as described in Fig-
ure 2. The surface expression of hBST-2 on pNL4-3-co-transfected (opened bars and circles) and pNL43-Udel-co-transfected 
(gray bars and circles) cells was analyzed by flow cytometry. MFI is represented in bars (Y-axis on left), and the percentage of 
hBST-2-positive cells is represented in circles (Y-axis on right, log scale). All experiments were performed in triplicate. Statisti-
cal significance (Student's t test) versus wild-type HIV-1 values is represented as follows: *, P < 0.05; **, P < 0.01. Error bars 
indicate standard deviations.Retrovirology 2009, 6:53 http://www.retrovirology.com/content/6/1/53
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Marburg virus [18,19]. Therefore, further studies on the
mechanism of BST-2 function will provide beneficial
information leading to novel therapeutic strategies
against several virus-induced diseases including AIDS.
Methods
Cell culture
HEK293 cells (human kidney), Vero cells (AGM kidney),
Cos-7 cells (AGM kidney), rabbit skin cells (RSC, kindly
provided by Dr. B. Roizman), and TZM-bl cells (obtained
from AIDS reagent program, National Institute of Health)
were maintained in low-glucose DMEM (Nikken) con-
taining 10% FCS and antibiotics. D-17 cells (canine oste-
osarcoma), CRFK cells (feline kidney), PK-15 cells
(porcine kidney), Mv.1.Lu cells (Mustela vison, mink
lung), and QT6 cells (Coturnix coturnix japonica, quail fib-
rosarcoma) were maintained in high-glucose DMEM
(Sigma) containing 10% FCS, 2 mM GlutaMax (Invitro-
gen), and antibiotics. PtK2 cells (potoroo kidney) were
maintained in Eagle's minimum essential medium
(Sigma) supplemented with 1 mM sodium pyruvate, 2
mM GlutaMax, 10% FCS and antibiotics. MT-4 cells were
maintained in RPMI1640 (Nikken) containing 10% FCS
and antibiotics. Mv.1.Lu cells and QT6 cells were kindly
donated by Dr. A. Koito.
Plasmid construction
To construct phBST-2, a bst-2  cDNA (GenBank:
NM_004335, bases 10-552) was amplified by polymerase
chain reaction from a human leukocyte cDNA library
(Invitrogen), and the resulting fragment was inserted into
peGFP-C1 (Clontech). Sequence of the construct was con-
firmed with an ABI 3130xl genetic analyzer (Applied Bio-
systems).
Transfection and virus preparation
Cells were seeded in 6-well plate to appropriate densities
1-day prior to transfection and were transfected by using
Lipofectamine 2000 reagent (Invitrogen) according to the
manufacture's protocol. Briefly, 1 μg of pNL4-3 [20] or
pNL43-Udel (kindly donated by Dr. K. Strebel) [1] was
cotransfected with 20 or 100 ng of phBST-2. The amount
of plasmid DNA for transfection was normalized to 2 μg
per well. Four hour after transfection, culture medium was
replaced freshly. The culture supernatant was harvested,
centrifuged, and then filtrated with 0.45-μm filter (Milli-
pore) to produce virus solutions at 24 hours post-transfec-
tion. All experiments were performed in triplicate. To
prepare wild-type or Vpu-deficient HIV-1 for its infection
assay, pNL4-3 or pNL43-Udel was transfected into
HEK293 cells by the calcium phosphate method as previ-
ously described [21]. The prepared viruses were titrated by
using peripheral blood mononuclear cells, and the
TCID50 was calculated as previously described [22].
TZM-bl assay
Quantification of the amount of released HIV-1 virion
was performed by using TZM-bl cells as previously
described [5]. Briefly, appropriate virus solution was inoc-
ulated into 1 × 105 TZM-bl cells per 12-well plate. The cells
were harvested at 48 hours post-infection, and β-galactos-
idase assay was performed by using Galacto-Star Mamma-
lian Reporter Gene Assay System (Applied Biosystems)
according to the manufacture's procedure. Activity was
measured with a 1420 ALBOSX multilabel counter (Per-
kin Elmer).
p24 ELISA
The amount of HIV-1 virion released from CRFK, PtK2,
and MT-4 cells was quantified by using HIV-1 p24 ELISA
kit (ZeptoMetrix) according to the manufacture's instruc-
tions.
Flow cytometry
Flow cytometry was performed as previously described
[21]. A mouse anti-hBST-2 monoclonal antibody
(donated by Chugai Pharmaceutical Co., Japan) [6,23]
and a Cy5-conjugated donkey anti-mouse IgG antisera
(Chemicon) were used. For costaining of cell surface
hBST-2 and intracellular p24, the anti-hBST-2 mono-
clonal antibody was pre-labelled with Zenon Alexa Fluor
647 mouse IgG2a labelling kit (Invitrogen) according to
the manufacture's protocol. Cell surface hBST-2 was
stained with the pre-labelled anti-hBST-2 antibody, and
Comparison of the level of exogenous hBST-2 on plasma membrane with its inhibition efficiency for HIV-1 release in various  cell lines Figure 4 (see previous page)
Comparison of the level of exogenous hBST-2 on plasma membrane with its inhibition efficiency for HIV-1 
release in various cell lines. (A and B) The results shown in Figures 2 and 3 were summarized and rearranged as follows: 
the level of surface expression of hBST-2 is shown in MFI (A) and the percentage of surface hBST-2 positive cells (B) in the X-
axis. To calculate % virus release (Y-axis), the infectivity of the culture supernatant of phBST-2-untransfected cells (for 
HEK293, Vero, Cos-7, D-17, RSC, Mv.1.Lu, and QT6 cells) or the amount of p24 in the culture supernatant of phBST-2-
untransfected cells (for CRFK and PtK2) was defined as 100%. Statistical significance of the correlation between the level of 
surface hBST-2 (X-axis, shown in MFI or % positive cells) and % virus release (Y-axis) in the results from the 9 analyzed cells 
(HEK293, Cos-7, D-17, CRFK, PK-15, RSC, Mv.1.Lu, PtK2, and QT6 cells) was determined by Pearson's correlation test, and P 
< 0.01 was considered significant. Approximation curve of the result from the 9 analyzed cells is drawn in gray lines, and a rep-
resentative result from Vero cells is drawn in broken line. r, Pearson's correlation coefficient.Retrovirology 2009, 6:53 http://www.retrovirology.com/content/6/1/53
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the cells were permeabiliezed and fixed with BD
Cytoperm/Cytofix solution (BD Pharmingen). Then,
intracellular p24 was stained with a FITC-conjugated anti-
HIV-1 p24 antibody (clone 2C2, kindly provided by Dr. Y.
Tanaka) [24].
Western blotting
Western blotting was performed as previously described
[21] with some modification. Briefly, the cells were lysed
with lysis buffer (1% NP-40, 50 mM Tris-HCl [pH7.5],
150 mM NaCl, 1 mM EDTA, 1 mM Na3VO4, and 1 mM
PMSF). The lysates were separated by SDS-PAGE and
transferred to Immobilon transfer membrane (Millipore).
For detection, the mouse anti-hBST-2 monoclonal anti-
body, a mouse anti-Tubulin monoclonal antibody (clone
DM1A; Sigma), and an HRP-conjugated horse anti-mouse
IgG antibody (Cell Signalling) were used. It has been
reported that hBST-2 is a highly glycosylated protein [25].
To remove the sugar chains in hBST-2 protein and detect
hBST-2 more clearly, the lysates were treated with glyco-
peptidase F (TaKaRa) according to the manufacture's pro-
cedure.
Statistical analyses
Student's t test was used to determine statistical signifi-
cance, and P < 0.05 and P < 0.01 were considered signifi-
cant. The Pearson correlation coefficient was applied to
determine statistical significance for the correlation
between the suppression efficiency for particle release by
hBST-2 and the level of surface hBST-2 in the 9 kinds of
cells lines (Figure 4), and P < 0.01 was considered signifi-
cant. Repeated measure ANOVA was applied to determine
statistical significance between Vero cells and the other
cell lines (Figure 4), and P < 0.01 was considered signifi-
cant.
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